Betamethasone Dipropionate Ointment USP, 0.05%* (Augmented) (Potency expressed as betamethasone),...
FDA Drug Recall #D-0850-2022 — Class II — April 21, 2022
Recall Summary
| Recall Number | D-0850-2022 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 21, 2022 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | McKesson Corporation dba McKesson Drug Company |
| Location | Memphis, TN |
| Product Type | Drugs |
| Quantity | 55,440 tubes |
Product Description
Betamethasone Dipropionate Ointment USP, 0.05%* (Augmented) (Potency expressed as betamethasone), 15 gram tube, Rx Only, Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310, Distributed by: McKesson Corporation dba Sky Packaging 4971 Southridge Blvd., Suite 101 Memphis, TN 38141, NDC 63739-996-65
Reason for Recall
CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.
Distribution Pattern
Nationwide in the United States including Guam and the Northern Mariana Islands.
Lot / Code Information
Lot: 15644, Exp.: 05/31/2022
Other Recalls from McKesson Corporation dba McKesson Dru...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0848-2022 | Class II | Lidocaine Hydrochloride Topical Solution USP 4%... | Apr 21, 2022 |
| D-0851-2022 | Class II | Erythromycin Topical Gel USP, 2%, Net Wt 60 g t... | Apr 21, 2022 |
| D-0847-2022 | Class II | Halobetasol Propionate Ointment 0.05% Net Wt., ... | Apr 21, 2022 |
| D-0849-2022 | Class II | Lidocaine Prilocaine Cream USP, 2.5%/2.5% Net W... | Apr 21, 2022 |
| D-0630-2021 | Class III | Levetiracetam Tablets USP, 250 mg UD 100 Tablet... | May 26, 2021 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.